A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007), or who re
Read time: 1 mins
Last updated:5th Jul 2011
The primary objective is to evaluate the antiviral efficacy of TMC435 in combination with PegIFNalpha-2a and RBV, with respect to the proportion of subjects with SVR24 (1) in the subjects who participated in the placebo group of a Phase II/III TMC435 study, and (2) in the subjects who participated in a selected Tibotec-sponsored Phase I study.
|Study start date||2011-07-05|